Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations
The improvement in supportive care and the introduction of new therapeutic agents,
including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have …
including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have …
Integrating patient-centered factors in the risk assessment of MDS
RJ Buckstein - Hematology 2014, the American Society of …, 2019 - ashpublications.org
Myelodysplastic syndromes are clonal myeloid neoplasms that primarily present in older
adults. Although leukemia develops in approximately 25% to 30% of individuals, the …
adults. Although leukemia develops in approximately 25% to 30% of individuals, the …
Mutations and prognosis in myelodysplastic syndromes: karyotype‐adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic …
N Gangat, M Mudireddy, TL Lasho… - American journal of …, 2018 - Wiley Online Library
To develop a genetic risk model for primary myelodysplastic syndromes (MDS), we queried
the prognostic significance of next‐generation sequencing (NGS)‐derived mutations, in the …
the prognostic significance of next‐generation sequencing (NGS)‐derived mutations, in the …
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis …
JC Hernández‐Boluda, A Pereira… - American journal of …, 2021 - Wiley Online Library
Allogeneic hematopoietic cell transplantation (allo‐HCT) is increasingly used in older
myelofibrosis (MF) patients, but its risk/benefit ratio compared to non‐transplant approaches …
myelofibrosis (MF) patients, but its risk/benefit ratio compared to non‐transplant approaches …
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish …
Isolate loss of chromosome Y (-Y) in myelodysplastic syndromes (MDS) is associated to a
better outcome but it is also well described as an age-related phenomenon. In this study we …
better outcome but it is also well described as an age-related phenomenon. In this study we …
The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population‐based study
X Ye, D Chen, Y Zheng, C Wu, X Zhu… - Hematological …, 2019 - Wiley Online Library
To determine the incidence, risk factors, and relative survival of acute myeloid leukemia
(AML) secondary to myelodysplastic syndrome (MDS) in the Surveillance, Epidemiology …
(AML) secondary to myelodysplastic syndrome (MDS) in the Surveillance, Epidemiology …
Prognostic effect of RUNX1 mutations in myelodysplastic syndromes: a meta-analysis
W He, C Zhao, H Hu - Hematology, 2020 - Taylor & Francis
Objectives RUNX1 mutations have been widely found in patients with myelodysplastic
syndrome (MDS). Majority of reports revealed that RUNX1 mutations are associated with a …
syndrome (MDS). Majority of reports revealed that RUNX1 mutations are associated with a …
Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity
Y Madanat, MA Sekeres - Seminars in hematology, 2017 - Elsevier
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem
cell disorders that have a substantial impact on patients' quality of life, in addition to causing …
cell disorders that have a substantial impact on patients' quality of life, in addition to causing …
[HTML][HTML] Integration Analysis of JAK2 or RUNX1 Mutation With Bone Marrow Blast Can Improve Risk Stratification in the Patients With Lower Risk Myelodysplastic …
Y Fang, J Guo, D Wu, LY Wu, LX Song, Z Zhang… - Frontiers in …, 2021 - frontiersin.org
Despite the improvements in prognostication of the revised International Prognostic Scoring
System (IPSS-R) in myelodysplastic syndrome (MDS), there remain a portion of patients with …
System (IPSS-R) in myelodysplastic syndrome (MDS), there remain a portion of patients with …
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the …
X Calvo, L Arenillas, E Luño, L Senent… - American Journal of …, 2017 - Wiley Online Library
Abstract The Revised International Prognostic Scoring System (IPSS‐R) has been
recognized as the score with the best outcome prediction capability in MDS, but this brought …
recognized as the score with the best outcome prediction capability in MDS, but this brought …